open access

Online first
Published online: 2021-10-05
Get Citation

Biomarkers for atrial fibrillation and chronic kidney disease: what are the evidences?

Rungroj Krittayaphong1, Komsing Methavigul
DOI: 10.33963/KP.a2021.0124
Pubmed: 34611881
  1. Division of Cardiology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

open access

Online first
Published online: 2021-10-05


Not available


Not available
Get Citation
About this article

Biomarkers for atrial fibrillation and chronic kidney disease: what are the evidences?


Kardiologia Polska (Polish Heart Journal)


Online first

Article type


Published online







Rungroj Krittayaphong
Komsing Methavigul

References (15)
  1. Ding WY, Gupta D, Wong CF, et al. Pathophysiology of atrial fibrillation and chronic kidney disease. Cardiovasc Res. 2021; 117(4): 1046–1059.
  2. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Revista Española de Cardiología (English Edition). 2021; 74(5): 437.
  3. Piccini J, Stevens S, Chang Y, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 2013; 127(2): 224–232.
  4. Hijazi Z, Oldgren J, Lindbäck J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016; 387(10035): 2302–2311.
  5. Fox KAA, Lucas JE, Pieper KS, et al. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 2017; 7(12): e017157.
  6. Guo Y, Zhu H, Chen Y, et al. Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation. Am J Med. 2018; 131(2): 185–192.
  7. Matusik PT, Leśniak WJ, Heleniak Z, et al. Thromboembolism and bleeding in patients with atrial fibrillation and stage 4 chronic kidney disease: impact of biomarkers. Kardiol Pol. 2021 [Epub ahead of print].
  8. Lind L, Wallentin L, Kempf T, et al. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J. 2009; 30(19): 2346–2353.
  9. Wallentin L, Hijazi Z, Andersson U, et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014; 130(21): 1847–1858.
  10. Inker L, Schmid C, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012; 367(1): 20–29.
  11. Chantrarat T, Krittayaphong R. Oral anticoagulation and cardiovascular outcomes in patients with atrial fibrillation and chronic kidney disease in Asian Population, Data from the COOL-AF Thailand registry. Int J Cardiol. 2021; 323: 90–99.
  12. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021 [Epub ahead of print].
  13. Chong DTt, Andreotti F, Verhamme P, et al. Direct oral anticoagulants in asian patients with atrial fibrillation: consensus recommendations by the asian pacific society of cardiology on strategies for thrombotic and bleeding risk management. Eur Cardiol. 2021; 16: e23.
  14. Chiang CE, Wang KL, Lip GYH. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost. 2014; 111(5): 789–797.
  15. Chantrarat T, Krittayaphong R. The clinical outcomes of different eGFR strata and time in therapeutic range in atrial fibrillation patients with chronic kidney disease: a nationwide cohort study. Curr Probl Cardiol. 2021; 46(9): 100838.


Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: